NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Merck & Co., Inc. (NYSE:MRK) on behalf of long-term stockholders following a class action complaint that was filed against Merck on February 12, 2025 with a Class Period from February 3, 2022, to February 3, 2025. Our investigation concerns whether the board of directors of Merck have breached their fiduciary duties to the company.The Merck class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) defendants created the false impression that they possessed reliable information pertaining to Merck's projected revenue outlook and anticipated growth of Gardasil while also minimizing risk from competition and drug approval development, such as China's approval to shift Gardasil to a 2-dose regimen; (ii) in truth, Merck's optimistic reports of growth, claims of successful consumer activation and education in China, overall ability ...Full story available on Benzinga.com
Merck is a New Jersey-based multinational biopharmaceutical company that develops and commercializes novel therapeutics and vaccines for the treatment of a range of diseases.